Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT

Bone Marrow Transplantation

Volumn 45, Issue 4, 2010, Pages 781-782

  Oshima, K ^a   Sato, M ^a   Terasako, K ^a   Kimura, S ^a   Okuda, S ^a   Kako, S ^a   Kanda, Y ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; CLINICAL STUDY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG TARGETING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; MORTALITY; NEPHROTOXICITY; ORGAN DONOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 77950627915     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.213     Document Type: Letter

References (11)

1. Ram R, Gafter-Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009; 43: 643-653.
2. Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Kodera Y et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 181-185.
3. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
4. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314.
5. Yanada M, Emi N, Naoe T, Sakamaki H, Takahashi S, Hirabayashi N et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant 2004; 34: 331-337.
6. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764.
7. Nakamura Y, Takeuchi H, Okuyama K, Akashi T, Jojima Y, Konno O et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. Transplant Proc 2005; 37: 1725-1727.
8. Ogawa N, Kanda Y, Matsubara M, Asano Y, Nakagawa M, Sakata-Yanagimoto M et al. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transplant 2004; 33: 549-552.
9. Couriel DR, Thall P, Mickler K, De Lima M, Giralt S, Qazilbash MH et al. Phase II/III randomized study comparing two different tacrolimus blood levels for the prevention of graft-versus-host disease (GVHD). Blood 2005; 106: 45a (abstract 142).
10. Wingard JR, Nash RA, Przepiorka D, Klein JL, Weisdorf DJ, Fay JW et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant 1998; 4: 157-163.
11. Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H et al. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol 2008; 83: 226-232.